Journal: International Journal of General Medicine

Article Title: Effects of Sintilimab Plus Radiotherapy on Levels of Spondin-2 and Glucose Transporter-1 in Patients with Cervical Cancer

doi: 10.2147/IJGM.S461606

Figure Lengend Snippet: Levels of Serum Tumor Markers Before and After Six Cycles of Treatment ( \documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document} $\bar x\pm s$\end{document} )

Article Snippet: Then the levels of carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC-Ag), vascular endothelial growth factor-A (VEGF-A) and vascular endothelial growth factor receptor 2 (VEGFR2) were measured by enzyme-linked immunosorbent assay (ELISA) in strict accordance with the instructions of kits provided by Wuhan CUSABIO Co., Ltd. (China) and Shanghai Jining Biological Preparation Co., Ltd. (China). (4) Levels of Spondin-2 and Glut-1: The levels of serum Spondin-2 and Glut-1 were measured by ELISA before treatment and after six cycles of treatment. (5) Survival status: All patients were followed up by outpatient visit or telephone calls for 18 months to record their survival status.

Techniques: Control

Journal: Molecular medicine reports

Article Title: Antitumor activity of an adenovirus harboring two therapeutic genes, anti-VEGF ribozyme and human IL-24, in colon cancer.

doi: 10.3892/mmr_00000158

Figure Lengend Snippet: Figure 1. Schematic representation of the recombinant adenoviral vectors. An expression cassette containing (A) anti-VEGF ribozyme (Rz), (B) IL-24 and (C) anti-VEGF ribozyme + IL-24 (Rz/IL-24) was inserted into the deleted E1 region.

Article Snippet: The amplification conditions consisted of an initial 5-min denaturation step at 94 ̊C, followed by 50 cycles of 95 ̊C for 15 sec and 60 ̊C for 60 sec. To quantify the secreted VEGF protein in conditioned media from cells, human VeGF eliSa was performed using a human VeGF eliSa Kit (Boster, china) following the manufacturer's protocol with 100-μl samples diluted 1:50.

Techniques: Recombinant, Expressing

Journal: Molecular medicine reports

Article Title: Antitumor activity of an adenovirus harboring two therapeutic genes, anti-VEGF ribozyme and human IL-24, in colon cancer.

doi: 10.3892/mmr_00000158

Figure Lengend Snippet: Figure 2. Expression of anti-VEGF ribozyme RNA and IL-24 mRNA and protein in viral infected HT-29. A: (a) RT-PCR demonstrated that HT-29 cells did not express IL-24. Lane 1, marker; lane 2, cDNA from untreated HT-29 cells where no IL-24 expression was noted; lane 3, negative control, PCR for plasmid of pTrack-CMV-Rz; and lane 4, positive control, PCR for plasmid of pTrack-CMV-IL-24. A 621-bp DNA fragment was noted. (b) RT-PCR analysis of the expres sion of anti-VEGF ribozyme and IL-24 RNA in HT-29 cells. Lane 1, IL-24 in cells infected with Ad-IL-24; lane 2, anti-VEGF ribozyme with an expected length of 162 bp in cells infected with Ad-Rz; lane 3, marker; lane 4, IL-24 in cells infected with Ad-Rz/IL-24; and lane 5, anti-VEGF ribozyme in cells infected with Ad-Rz/IL-24 with an expected length of 214 bp. B: Results of immunofluorescence staining of IL-24 protein expression in cells treated with (c) PBS, (d) Ad-IL-24 and (e) Ad-Rz/IL-24. Left, light microscopy; right, fluorescence microscopy.

Article Snippet: The amplification conditions consisted of an initial 5-min denaturation step at 94 ̊C, followed by 50 cycles of 95 ̊C for 15 sec and 60 ̊C for 60 sec. To quantify the secreted VEGF protein in conditioned media from cells, human VeGF eliSa was performed using a human VeGF eliSa Kit (Boster, china) following the manufacturer's protocol with 100-μl samples diluted 1:50.

Techniques: Expressing, Infection, Reverse Transcription Polymerase Chain Reaction, Marker, Negative Control, Plasmid Preparation, Positive Control, Immunofluorescence, Staining, Light Microscopy, Fluorescence, Microscopy

Journal: Molecular medicine reports

Article Title: Antitumor activity of an adenovirus harboring two therapeutic genes, anti-VEGF ribozyme and human IL-24, in colon cancer.

doi: 10.3892/mmr_00000158

Figure Lengend Snippet: Figure 3. Cells treated with Ad-Rz/IL-24, Ad-IL-24 and Ad-Rz expressed reduced levels of VEGF. (A) Real-time PCR results, (B) ELISA results of VEGF protein secretion.

Article Snippet: The amplification conditions consisted of an initial 5-min denaturation step at 94 ̊C, followed by 50 cycles of 95 ̊C for 15 sec and 60 ̊C for 60 sec. To quantify the secreted VEGF protein in conditioned media from cells, human VeGF eliSa was performed using a human VeGF eliSa Kit (Boster, china) following the manufacturer's protocol with 100-μl samples diluted 1:50.

Techniques: Real-time Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay

Journal: Oncotarget

Article Title: γ-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model

doi:

Figure Lengend Snippet: A, γ-tocotrienol inhibited HUVEC migration. An IBIDI culture insert (IBIDI GmbH) consists of two reservoirs separated by a 500 μm thick wall created by a culture insert in a 35mm petri dish. An equal number of HUVECs (70 μl; 5×10 5 cells/ml) were added into the two reservoirs of the same insert and incubated at 37°C/5% CO2. After 12 hours, the insert was gently removed creating a gap of ~500 μm. The cells were treated with 50 μM γ-tocotrienol for 12 h before being exposed to 10ng/mL VEGF for 24 h. Width of wound was measured at time zero and 24h of incubation with and without γ-tocotrienol. The representative photographs showed the same area at time zero and after 24 h of incubation. B, γ-tocotrienol inhibited HUVEC invasion through matrigel coated polycarbonate membrane. After pre-incubation with or without 50 μM γ-tocotrienol for 12 h, transwell chambers were then placed into the wells of a 24-well plate, in which we had added Medium 200 containing 10 ng/mL VEGF. After incubation for 24h cell invasion was analyzed and columns represent mean number of invaded cells. C, γ-Tocotrienol inhibited the VEGF-induced tube formation of endothelial cells in matrigel. After incubation, endothelial cells were fixed, and tubular structures were photographed (magnification, ×100). D, γ-Tocotrienol significantly inhibited the VEGF-induced cell survival of HUVECs. Cell viability was determined by MTT assay. *, p < 0.01 versus VEGF alone.

Article Snippet: Human recombinant vascular endothelial growth factor (VEGF) and growth factor reduced (GFR) matrigel matrix were purchased from BD Biosciences (CA, USA).

Techniques: Migration, Incubation, MTT Assay

Journal: Oncotarget

Article Title: γ-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model

doi:

Figure Lengend Snippet: Aortic segments isolated from Sprague-Dawley rats were placed in the Matrigel coated plated and then overlayed with matrigel and treated with VEGF in the presence or absence of γ-tocotrienol. A, Representative photographs of sprouts from the margins of aortic rings. B, The number of sprouts were counted manually and epressed as a bar diagram. *, p < 0.01 versus VEGF alone.

Article Snippet: Human recombinant vascular endothelial growth factor (VEGF) and growth factor reduced (GFR) matrigel matrix were purchased from BD Biosciences (CA, USA).

Techniques: Isolation

Journal: Oncotarget

Article Title: γ-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model

doi:

Figure Lengend Snippet: The rectangular filters papers contained VEGF alone or in combinaiton with γ-Tocotrienol. The representative photographs of control and γ-tocotrienol-treated CAMs were shown. B, The number of the microvessels was quantified manually and displayed as bar diagram *p < 0.01 versus VEGF alone. C, γ-Tocotrienol inhibits VEGF-induced angiogenesis in vivo . Six-week-old C57/BL/6 mice were injected with 0.5 mL of matrigel containing 10 or 20 μg γ-tocotrienol, 100 ng of VEGF, and 20 units of heparin into the ventral area (n = 5 per group). After 6 days, the skin of mice was pulled back to expose the intact Matrigel plugs and were photographed. D, γ-Tocotrienol inhibited blood vessel formation. The Matrigel plugs were fixed, sectioned, and stained with H&E (magnification, ×200).

Article Snippet: Human recombinant vascular endothelial growth factor (VEGF) and growth factor reduced (GFR) matrigel matrix were purchased from BD Biosciences (CA, USA).

Techniques: In Vivo, Injection, Staining

Journal: Oncotarget

Article Title: γ-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model

doi:

Figure Lengend Snippet: A) Immunohistochemical analysis of Ki-67, VEGF, CD31, and cleaved caspase-3 showed the inhibition in expression of Ki-67, VEGF, and CD31 and increased levels of cleaved caspase-3 expression in γ-tocotrienol treated samples as compared with control group. Percentage indicates positive staining for the given biomarker. The photographs were taken at the magnification of 40 X. B) Western blot analysis of p-AKT, VEGF and cleaved caspase-3 proteins indicated a decrease in the expression of p-AKT and VEGF and increase in levels of cleaved caspase-3 expression in γ-tocotrienol treated samples as compared with control group. C) Effect of γ-tocotrienol on tumor-induced angiogenesis in-vivo . SCID mice were injected with 0.4 ml of Matrigel containing 5 × 10 6 single cell suspensions freshly derived from HCC patients (designated as HCC180811 and HCC 020113) and 20 units heparin with or without γ-tocotrienol (20 μg). Gross appearance of matrigel plugs retrieved from SCID mice 7 days post-injection were shown.

Article Snippet: Human recombinant vascular endothelial growth factor (VEGF) and growth factor reduced (GFR) matrigel matrix were purchased from BD Biosciences (CA, USA).

Techniques: Immunohistochemical staining, Inhibition, Expressing, Staining, Biomarker Assay, Western Blot, In Vivo, Injection, Derivative Assay